Pancreatic cancer is a disease that has a very high fatality rate and one of the highest
mortality ratios among all major cancers, remaining the fourth leading cause of cancer …

Pancreatic cancer (PC), particularly its most common form, pancreatic ductal
adenocarcinoma (PDAC), is relatively rare but highly lethal. Knowledge about PC risk …

Background Effective treatment options for advanced pancreatic cancer are finite. NAPOLI-1,
a phase III randomized trial, demonstrated the efficacy of nanoliposomal irinotecan with …

Background: Metastasis accounts for the most lethal reason for the death of ovarian cancer
patients, but remains largely untreated. Epithelial–mesenchymal transition (EMT) is critical …

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy with
minimal treatment options and a global rise in prevalence. PDAC is characterized by …

Pancreatic cancer is one of the fatal causes of global cancer-related deaths. Although
surgery and chemotherapy are standard treatment options, post-treatment outcomes often …

Despite extensive research in the pathogenesis, early detection, and therapeutic
approaches of pancreatic ductal adenocarcinoma (PDAC), it remains a devastating and …

Pancreatic ductal adenocarcinoma (PDAC) is one of the major causes of death in the
Western world, and it is estimated to become the second leading cause of tumour-related …

Pancreatic cancer (PC) is characterized by (epi) genetic and microenvironmental alterations
that negatively impact the treatment outcomes. New targeted therapies have been pursued …

Background Despite the remarkable advances in the early diagnosis and treatment, overall
5-year survival rate of patients with pancreatic cancer is less than 10%. Gemcitabine (GEM) …